We are live on ! Find out more
RANI icon

Rani Therapeutics

34 hedge funds and large institutions have $10.9M invested in Rani Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more capital invested

Capital invested by funds: $6.96M → $10.9M (+$3.98M)

0.17% more ownership

Funds ownership: 12.57%12.73% (+0.17%)

0% more funds holding

Funds holding: 3434 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $27K

Holders
34
Holders Change
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
2
Increased
4
Reduced
7
Closed
2
Calls
Puts
$27K
Net Calls
-$27K
Net Calls Change
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
Simplex Trading
26
Simplex Trading
Illinois
$30K +$18.3K +7,893 +635%
JP Morgan Chase
27
JP Morgan Chase
New York
$12.3K -$1.71K -741 -17%
AF
28
Allworth Financial
California
$10.4K
TRCT
29
Tower Research Capital (TRC)
New York
$7.66K +$5.34K +2,308 New
IWP
30
IAG Wealth Partners
Wisconsin
$3.34K
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$1.03K
Wells Fargo
32
Wells Fargo
California
$339 +$18 +8 +9%
Qube Research & Technologies (QRT)
33
Qube Research & Technologies (QRT)
United Kingdom
$10
Millennium Management
34
Millennium Management
New York
-$100K -46,137 Closed
UBS Group
35
UBS Group
Switzerland
-$12.4K -5,700 Closed
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
-$72 -31 -72%

RANI Hedge Fund Activity: Q4 2023 in Review

34 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2023, worth a combined $10.9M — up 57% from $6.96M a quarter earlier.

Fund positioning in RANI was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 7 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $22K. The largest seller was Bank of America, cutting an estimated $215K.

  • 34 institutional investors held Rani Therapeutics (RANI) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $10.9M of Rani Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
  • 2 funds opened new Rani Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
  • The largest Rani Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $22K added.
  • The largest Rani Therapeutics seller in Q4 2023 was Bank of America, an estimated $215K sold.

Based on aggregated 13F filings for Q4 2023.